Collegium Pharmaceutical Inc
COLL48.880USD
-0.450-0.91%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
1.54BMarket Cap
26.58P/E TTM
More Details of Collegium Pharmaceutical Inc Company
Collegium Pharmaceutical, Inc. is a diversified biopharmaceutical company. The Company has developed, licensed, and acquired a portfolio of products for use in the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. Its commercial products include Jornay PM (Jornay), Belbuca, Xtampza ER (Xtampza), Nucynta ER and Nucynta IR (Nucynta Products), and Symproic in the United States. Its Jornay is a central nervous system (CNS) stimulant prescription medicine for the treatment of ADHD. The Belbuca is a buccal film that contains buprenorphine for severe and persistent pain. Xtampza ER is an abuse-deterrent, extended-release, oral formulation of oxycodone. The Xtampza ER is a pain treatment option designed with abuse deterrent properties. The Nucynta Products are ER and IR oral formulations of tapentadol. Nucynta ER is indicated for the management of severe and persistent pain that requires an extended treatment period with a daily opioid analgesic.
Collegium Pharmaceutical Inc Info
Ticker SymbolCOLL
Company nameCollegium Pharmaceutical Inc
IPO dateMay 07, 2015
CEOKarnani (Vikram)
Number of employees357
Security typeOrdinary Share
Fiscal year-endMay 07
Address100 Technology Center Dr
CitySTOUGHTON
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02072-4710
Phone17817133699
Websitehttps://www.collegiumpharma.com/
Ticker SymbolCOLL
IPO dateMay 07, 2015
CEOKarnani (Vikram)
Company Executives of Collegium Pharmaceutical Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
96.99K
-8.48%
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
44.83K
+27.23%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
30.12K
-10.81%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Director
Independent Director
19.58K
--
Ms. Colleen Tupper
Ms. Colleen Tupper
Chief Financial Officer, Executive Vice President
Chief Financial Officer, Executive Vice President
12.18K
-71.12%
Mr. Garen G. Bohlin
Mr. Garen G. Bohlin
Independent Director
Independent Director
--
--
Dr. John A. Fallon, M.D.
Dr. John A. Fallon, M.D.
Independent Director
Independent Director
--
--
Ms. Jane Gonnerman
Ms. Jane Gonnerman
Executive Vice President - Strategy and Corporate Development
Executive Vice President - Strategy and Corporate Development
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Vikram Karnani
Mr. Vikram Karnani
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
96.99K
-8.48%
Mr. David Dieter
Mr. David Dieter
Executive Vice President, General Counsel, Corporate Secretary
Executive Vice President, General Counsel, Corporate Secretary
68.45K
--
Mr. Gino Santini
Mr. Gino Santini
Independent Chairman of the Board
Independent Chairman of the Board
44.83K
+27.23%
Dr. Rita J. Balice-Gordon, Ph.D.
Dr. Rita J. Balice-Gordon, Ph.D.
Independent Director
Independent Director
30.12K
-10.81%
Ms. Nancy S. Lurker
Ms. Nancy S. Lurker
Independent Director
Independent Director
22.52K
+76.94%
Dr. Carlos V. Paya, M.D., Ph.D.
Dr. Carlos V. Paya, M.D., Ph.D.
Independent Director
Independent Director
19.58K
--
Revenue Breakdown
Currency: USDUpdated: Mon, Oct 6
Currency: USDUpdated: Mon, Oct 6
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
By BusinessUSD
Name
Revenue
Proportion
Nucynta IR
79.10M
42.08%
Xtampza ER
52.60M
27.98%
Belbuca
52.60M
27.98%
Jomay PM
32.63M
17.35%
Nucynta ER
19.95M
10.61%
Symproic
3.72M
1.98%
Relevant data have not been disclosed by the company yet.
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Nucynta IR
79.10M
42.08%
Xtampza ER
52.60M
27.98%
Belbuca
52.60M
27.98%
Jomay PM
32.63M
17.35%
Nucynta ER
19.95M
10.61%
Symproic
3.72M
1.98%
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.40%
Rubric Capital Management LP
8.94%
Eventide Asset Management, LLC
7.56%
The Vanguard Group, Inc.
6.99%
Renaissance Technologies LLC
5.06%
Other
57.05%
Shareholders
Shareholders
Proportion
BlackRock Institutional Trust Company, N.A.
14.40%
Rubric Capital Management LP
8.94%
Eventide Asset Management, LLC
7.56%
The Vanguard Group, Inc.
6.99%
Renaissance Technologies LLC
5.06%
Other
57.05%
Shareholder Types
Shareholders
Proportion
Investment Advisor
54.52%
Investment Advisor/Hedge Fund
36.45%
Hedge Fund
20.63%
Research Firm
6.34%
Individual Investor
1.66%
Pension Fund
1.39%
Bank and Trust
0.47%
Sovereign Wealth Fund
0.44%
Venture Capital
0.05%
Institutional Shareholding
Updated: Mon, Dec 8
Updated: Mon, Dec 8
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
508
38.05M
128.10%
+16.29K
2025Q3
519
38.04M
130.05%
+1.27M
2025Q2
505
36.77M
132.27%
-822.29K
2025Q1
512
37.63M
134.52%
-5.59M
2024Q4
511
38.06M
137.82%
-1.43M
2024Q3
486
39.57M
141.89%
-1.42M
2024Q2
473
40.59M
134.94%
+186.99K
2024Q1
449
40.40M
133.69%
-3.32M
2023Q4
422
40.01M
132.42%
+446.16K
2023Q3
413
39.57M
125.51%
-587.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
BlackRock Institutional Trust Company, N.A.
4.70M
14.93%
-135.32K
-2.80%
Jun 30, 2025
Rubric Capital Management LP
3.13M
9.94%
-25.00K
-0.79%
Aug 13, 2025
Eventide Asset Management, LLC
2.64M
8.38%
+1.85K
+0.07%
Jun 30, 2025
The Vanguard Group, Inc.
2.23M
7.08%
-8.14K
-0.36%
Jun 30, 2025
Renaissance Technologies LLC
1.52M
4.83%
--
--
Jun 30, 2025
Fuller & Thaler Asset Management Inc.
1.43M
4.54%
+59.58K
+4.34%
Jun 30, 2025
Principal Global Investors (Equity)
1.47M
4.66%
-106.48K
-6.77%
Jun 30, 2025
State Street Investment Management (US)
1.35M
4.3%
-20.59K
-1.50%
Jun 30, 2025
Emerald Advisers LLC
1.39M
4.41%
-12.37K
-0.88%
Jun 30, 2025
Janus Henderson Investors
469.55K
1.49%
+39.07K
+9.08%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
Invesco Biotechnology & Genome ETF
3.23%
Invesco Pharmaceuticals ETF
2.49%
Pacer US Small Cap Cash Cows Growth Leaders ETF
1.8%
Ballast Small/Mid Cap ETF
1.79%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
1.53%
State Street SPDR S&P Pharmaceuticals ETF
1.37%
Janus Henderson Small Cap Growth Alpha ETF
1.07%
Invesco S&P SmallCap 600 Pure Growth ETF
1.03%
VictoryShares Small Cap Free Cash Flow ETF
0.81%
Invesco S&P SmallCap Health Care ETF
0.69%
View more
Invesco Biotechnology & Genome ETF
Proportion3.23%
Invesco Pharmaceuticals ETF
Proportion2.49%
Pacer US Small Cap Cash Cows Growth Leaders ETF
Proportion1.8%
Ballast Small/Mid Cap ETF
Proportion1.79%
Direxion Daily Pharmaceutical & Medical Bl 3X ETF
Proportion1.53%
State Street SPDR S&P Pharmaceuticals ETF
Proportion1.37%
Janus Henderson Small Cap Growth Alpha ETF
Proportion1.07%
Invesco S&P SmallCap 600 Pure Growth ETF
Proportion1.03%
VictoryShares Small Cap Free Cash Flow ETF
Proportion0.81%
Invesco S&P SmallCap Health Care ETF
Proportion0.69%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Collegium Pharmaceutical Inc?
The top five shareholders of Collegium Pharmaceutical Inc are:
BlackRock Institutional Trust Company, N.A. holds 4.70M shares, accounting for 14.93% of the total shares.
Rubric Capital Management LP holds 3.13M shares, accounting for 9.94% of the total shares.
Eventide Asset Management, LLC holds 2.64M shares, accounting for 8.38% of the total shares.
The Vanguard Group, Inc. holds 2.23M shares, accounting for 7.08% of the total shares.
Renaissance Technologies LLC holds 1.52M shares, accounting for 4.83% of the total shares.
BlackRock Institutional Trust Company, N.A. holds 4.70M shares, accounting for 14.93% of the total shares.
Rubric Capital Management LP holds 3.13M shares, accounting for 9.94% of the total shares.
Eventide Asset Management, LLC holds 2.64M shares, accounting for 8.38% of the total shares.
The Vanguard Group, Inc. holds 2.23M shares, accounting for 7.08% of the total shares.
Renaissance Technologies LLC holds 1.52M shares, accounting for 4.83% of the total shares.
What are the top three shareholder types of Collegium Pharmaceutical Inc?
The top three shareholder types of Collegium Pharmaceutical Inc are:
BlackRock Institutional Trust Company, N.A.
Rubric Capital Management LP
Eventide Asset Management, LLC
BlackRock Institutional Trust Company, N.A.
Rubric Capital Management LP
Eventide Asset Management, LLC
How many institutions hold shares of Collegium Pharmaceutical Inc (COLL)?
As of 2025Q4, 508 institutions hold shares of Collegium Pharmaceutical Inc, with a combined market value of approximately 38.05M, accounting for 128.10% of the total shares. Compared to 2025Q3, institutional shareholding has increased by -1.95%.
What is the biggest source of revenue for Collegium Pharmaceutical Inc?
In FY2025Q2, the Nucynta IR business generated the highest revenue for Collegium Pharmaceutical Inc, amounting to 79.10M and accounting for 42.08% of total revenue.
